PRESCRIPTION DRUG IMPORT ACT
SB1971 creates the Wholesale Prescription Drug Importation Program Act and directs the Illinois Department of Public Health to establish a state-run program to import certain prescription drugs, primarily from Canadian suppliers, for sale in Illinois at lower cost. The department would contract with wholesalers and suppliers, create a registration process for participating health benefit plan issuers, health care providers, and pharmacies, publish a list of eligible drugs and prices, and operate outreach and a call center or electronic portal to explain the program.
The bill limits imported drugs to products that meet federal and state safety and legality requirements, are expected to generate consumer savings, and are not among several excluded categories such as controlled substances, biological products, infused drugs, intravenously injected drugs, inhaled surgical drugs, or parenteral drugs. It also allows the department to expand the program by rule to other countries if federal law permits, and requires annual reporting, auditing of participating wholesalers, rulemaking, and compliance with federal tracking, tracing, verification, and identification standards. The act would take effect July 1, 2025.
If enacted, SB1971 would add a new chapter of Illinois law governing prescription drug importation and would assign the Department of Public Health new regulatory, contracting, reporting, and oversight duties. It would create a legal framework for importing eligible prescription drugs into Illinois, establish participation rules for pharmacies and health care entities, and authorize the department to set fees or other funding mechanisms to administer the program. The bill also contemplates federal waiver or authorization requirements, meaning implementation of some provisions could depend on federal approval.
Based on the bill text and available context, the measure appears to be framed as a consumer cost-savings and access initiative, with no recorded committee debate or votes in the provided materials. The overall tone of the proposal is policy-driven and supportive of lowering prescription drug prices through regulated importation. Because there is no transcript or voting history, there is no documented opposition or formal support to characterize beyond the bill’s stated purpose.
The main points of potential contention are the use of Canadian suppliers and the broader importation of prescription drugs, which raises federal compliance, safety, patent, and supply-chain oversight issues. The bill addresses these concerns by requiring compliance with FDA standards, federal tracking and verification rules, and by excluding several drug categories from eligibility. Another likely issue is implementation: the department would need to secure federal authorization where required, develop rules and infrastructure, and determine funding, all of which could draw scrutiny from regulators, wholesalers, pharmacies, and pharmaceutical interests.